Innovating cancer drug discovery with refined phenotypic screens
Z Wang, A Hulikova, P Swietach - Trends in Pharmacological Sciences, 2024 - cell.com
Before molecular pathways in cancer were known to a depth that could predict targets, drug
development relied on phenotypic screening, where the effectiveness of candidate …
development relied on phenotypic screening, where the effectiveness of candidate …
HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer
A Besse, L Sedlarikova, L Buechler, M Kraus… - British Journal of …, 2024 - nature.com
Background Resistance to chemotherapy is a major problem in the treatment of patients with
triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on …
triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on …
Exploring a novel four-gene system as a diagnostic and prognostic biomarker for triple-negative breast cancer, using clinical variables
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis.
This research aims to find real hub genes for prognostic biomarkers of TNBC therapy. The …
This research aims to find real hub genes for prognostic biomarkers of TNBC therapy. The …